Our findings in a small number of patients suggest that PD-1/PD-L1 combination therapy has the potential to augment the efficacy of PD-1 treatment with tislelizumab in selected tumour types; however, further investigation in larger-scale studies is warranted. The gene discussed is PDCD1; the disease is neoplasm.